In vivo study | In ABT-751, the Calu-6 transplanted tumor model was treated with 100 and 75 mg/kg per day, which had significant anticancer activity. When combined with Cisplatin, ABT-751 further delayed tumor growth, which was dose dependent. ABT-751 alone in HT-29 colon transplantation tumor model, also has significant anticancer activity, when combined with 5-FU, further delay tumor growth, this effect also exists dose dependent. ABT-751 in dogs with lymphoma, with dose-limiting toxicity, with anorexia Vomit, Diarrhea, with a maximum tolerated dose (MTD) of 350 mg/m(2) PO q24h. Furthermore, the mean AUC and CMAX were 350 μg-hour/mL and 5.55 μg/mL, respectively, at the maximum tolerated dose (MTD) of 0.9 mg/m(2) PO q24h ABT-751. |